02:03

Activating the immune system with CELMoDs to treat multiple myeloma

00:58

Highlights from COMy 2024: risk stratification, role of MRD, and immunotherapies

01:11

An update to the risk stratification of MGUS, SMM, and multiple myeloma

04:15

The role of bone marrow stromal cells in myeloma progression and drug resistance

02:21

Mezigdomide: a novel CELMoD showing promise in the treatment of R/R myeloma

07:14

CAR-Ts in multiple myeloma: their current role and the future

02:41

Access inequality to advanced myeloma therapies in low-to-middle-income countries

03:00

The role of the peptide-drug conjugate melflufen in multiple myeloma

02:20

Novel CAR-T products in the pipeline for multiple myeloma

01:00

Quadruplet induction therapy in newly diagnosed high-risk myeloma

02:22

Should we screen for and treat myeloma precursor conditions?

01:38

The genomic definition of high-risk myeloma

01:59

The importance of early diagnosis in AL amyloidosis to improve outcomes for patients

01:10

Exploring the next era of treating AL amyloidosis: role of birtamimab

03:48

The current treatment landscape in multiple myeloma

01:28

The role of the hematologist and cardiologist in treating patients with amyloidosis

01:14

Major unmet needs in amyloidosis: early diagnosis & addressing mechanisms of tissue damage

01:49

Is a cure on the horizon for myeloma?

02:31

The role of cilta-cel in the myeloma treatment landscape

01:15

Key clinical trials to look out for in the myeloma space in 2024

02:08

Vaccinations and infection prophylaxis in multiple myeloma

02:55

The addition of bortezomib to melphalan-based conditioning in multiple myeloma

03:01

The impact of TET2 mutations on hematopoietic stem cell resilience to immune-related stress

02:03

The current landscape of treatment for BPDCN

01:51

EASIX: a predictive parameter of AEs following CAR-T therapy in LBCL

04:09

Veno-occlusive disease as a post-transplant complication of HSCT

02:05

CAR T-cell therapy programs to improve access for patients with leukemia in Mexico

14:43

Current research into post-alloSCT maintenance therapy in AML

01:50

The recent expanded approval of cilta-cel into earlier lines of myeloma therapy

01:46

Treosulfan versus busulfan-based conditioning for HSCT in transfusion-dependent thalassemia

02:42

MRD to identify those who benefit the most from FLT3 inhibition with gilteritinib in CR1 of AML

10:40

The impact of donor KIR genotypes on alloSCT outcomes in AML/MDS, and the value of biobanks

04:15

Using MRD to guide post-alloSCT treatment decisions in AML

05:20

Targeted therapies in AML: menin, FLT3 and IDH inhibitors

01:56

Addressing access inequality in CAR-T therapies

02:13

Frontline treatment of transplant eligible patients with myeloma: current approach & future changes

10:31

Comparing haploSCT to other donor types in lymphoma treatment

03:26

Developments in the treatment of patients with FLT3-mutated AML

02:18

Treating patients with advanced-stage HL in the frontline and relapsed settings in 2024

06:38

Key papers in cardio-oncology from 2023 of relevance to hematologists

07:50

The ESC guidelines on cardio-oncology: incorporating the guidelines into clinical practice

01:34

The future role of AI models in hematology and the need for high-quality data sets

02:07

Treating young patients with MPN

01:50

The impact of living with chronic GvHD and the nurse's perspective on treating these patients

02:40

What can clinicians do to address the impact of transfusion-dependent thalassemia on patients' QoL?

01:17

Using an AI model to quantify under-utilization of alloSCT for AML in the UK

01:56

Approaching treatment selection and sequencing with the recent influx of BTK inhibitors in CLL

01:16

The future of ambulatory care in the treatment of hematological conditions and malignancies

03:04

Single- vs double-unit transfusion for patients with hematological disorders

04:16

The novel bioactive peptide QUB-2392 shows anti-leukemic effects in leukemia cell lines

01:49

Exciting therapeutic approaches in the AML space

02:27

Optimizing the delivery of care for patients with hemoglobinopathies in the UK

01:15

Tackling PD1i resistance in Hodgkin lymphoma

02:00

The effectiveness of ambulatory care for patients undergoing stem cell transplantation

01:06

The importance of shared-decision making when treating infants with hemophilia

02:04

The safety & efficacy of loperamide prior to stool sample results in patients undergoing SCT

02:24

Primary prevention against atherosclerosis in patients with hemophilia

03:05

The development of iNKT-CAR T-cells for hematological malignancies

02:40

The safety & efficacy of emicizumab in patients under 18 months with hemophilia A

00:52

The unmet needs that remain for patients with systemic mastocytosis